Navigate DOT compliance, MRO revenue complexity, and employer client concentration with an advisor who understands occupational health transactions.
Find Drug Testing Services Deals Without a BrokerDrug testing businesses serving transportation, construction, and healthcare clients trade at 3.5–6x EBITDA. Choosing a broker with occupational health M&A experience ensures proper separation of pass-through lab revenue, regulatory compliance review, and accurate valuation of recurring employer contracts.
Boutique firms specializing in occupational health, laboratory services, and compliance-driven B2B businesses. Understands DOT regulations, MRO margin structure, and strategic buyer dynamics.
Best for: Sellers with $1M+ EBITDA seeking PE-backed roll-up platforms or national occupational health acquirers.
Business brokers handling $1M–$10M transactions across industries. Less specialized but accessible for owners needing SBA-eligible deal structuring and local buyer introductions.
Best for: Owner-operators with $500K–$1M EBITDA using SBA 7(a) financing with a first-time entrepreneurial buyer.
Advisors embedded within or retained by PE-backed occupational health or background screening platforms actively acquiring drug testing collection networks.
Best for: Sellers open to equity rollover, willing to retain 10–20% minority stake under a platform growth strategy.
Skip the broker — find deals direct
DealFlow OS surfaces off-market Drug Testing Services targets with seller signals and outreach angles. No commission.
Have you sold a drug testing or occupational health compliance business before, and can you share anonymized deal details?
Industry-specific experience ensures the broker understands pass-through lab revenue, DOT compliance risk, and employer contract concentration issues that affect valuation.
How will you separate collection revenue from pass-through lab charges when presenting financials to buyers?
Pass-through lab costs inflate top-line revenue but carry near-zero margin. Misrepresentation here causes buyer re-trades or deal collapse during due diligence.
What is your target buyer pool — strategic acquirers, PE roll-ups, or SBA-funded individual buyers — and why?
The right buyer type determines deal structure, timeline, and price. Strategic and PE buyers pay higher multiples but require cleaner regulatory and contract documentation.
How do you handle regulatory compliance gaps discovered during buyer due diligence, such as expired collector certifications or DOT audit findings?
Undisclosed compliance issues can kill deals or reduce valuation. An experienced broker proactively surfaces and addresses these before going to market.
Most drug testing businesses sell at 3.5–6x EBITDA. Businesses with diversified employer contracts, DOT consortium management, and clean compliance records command the higher end of that range.
Yes, if not properly normalized. Buyers value true margin from collection and MRO services. A broker must recast financials to isolate collection revenue from low-margin lab pass-throughs before going to market.
Yes. Drug testing services are SBA 7(a) eligible. Most deals at this level include 10–15% buyer equity, an SBA loan, and a seller note of 5–10% held for 24 months tied to client retention.
Expect 12–18 months from preparation to close. Sellers who pre-organize collector certifications, client contracts, and three years of recast financials consistently close faster and at higher multiples.
More Drug Testing Services Guides
Find Brokers in Other Industries
DealFlow OS surfaces off-market targets, scores seller motivation, and writes your outreach. Free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers